CytomX Phase 2 breast cancer study: Arm A meets ORR endpoint but Arm B fails; program paused, partnership sought

CytomX Therapeutics, Inc.

Arm A in HR+/HER2- breast cancer met primary endpoint: ORR 15% (central review) in 47 patients unselected for CD166 expression.
Arm B (TNBC) did not pass futility boundary (ORR <10%); enrollment in Arms B and C discontinued.
Safety: 30% discontinued for AE; Grade 3+ ocular 15%, neuropathic 10%. Lower toxicity at 6 mg/kg dose.
Company will not further advance program alone due to financial market conditions; seeking a partnership.
CytomX intends to present full Phase 2 data at a medical conference in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.